在先前未经治疗的表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）中使用阿米万他单抗联合拉泽替尼。回复。 - Suppr | 超能文献

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Reply.

作者信息

Cho Byoung C, Sethi Seema, Spira Alexander I

机构信息

Yonsei University College of Medicine, Seoul, South Korea.

Janssen Research and Development, Spring House, PA.

出版信息

N Engl J Med. 2025 Feb 6;392(6):620-621. doi: 10.1056/NEJMc2414705.

DOI:10.1056/NEJMc2414705

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Reply.在先前未经治疗的表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）中使用阿米万他单抗联合拉泽替尼。回复。

N Engl J Med. 2025 Feb 6;392(6):620-621. doi: 10.1056/NEJMc2414705.

2

Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.Amivantamab 联合 Lazertinib 治疗未经治的 - 突变型晚期 NSCLC。

N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26.

3

Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA.MARIPOSA研究中一线使用阿美替尼联合拉泽替尼治疗既往未治疗的高危表皮生长因子受体（EGFR）改变的非小细胞肺癌的通俗概述

Future Oncol. 2025 May;21(12):1429-1444. doi: 10.1080/14796694.2025.2487407. Epub 2025 Apr 24.

4

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Amivantamab 联合化疗加或不加 lazertinib 治疗奥希替尼治疗后进展的 EGFR 突变型晚期 NSCLC：III 期 MARIPOSA-2 研究的主要结果。

Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.

5

Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations.在伴有表皮生长因子受体（EGFR）突变的非小细胞肺癌中，阿美替尼单抗联合拉泽替尼与拉泽替尼及奥希替尼的成本效益分析。

Front Pharmacol. 2025 May 2;16:1527614. doi: 10.3389/fphar.2025.1527614. eCollection 2025.

6

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.阿米万他单抗联合拉泽替尼与奥希替尼作为表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌一线治疗的疗效比较：MARIPOSA亚洲亚组研究

Lung Cancer. 2025 Mar 15;204:108496. doi: 10.1016/j.lungcan.2025.108496.

7

Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast.阿美替尼单抗+拉泽替尼治疗晚期非小细胞肺癌的皮肤不良事件缓解与管理策略：视频播客

Target Oncol. 2025 Jun 21. doi: 10.1007/s11523-025-01163-3.

8

Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer.MARIPOSA-2的通俗易懂总结：阿美替尼单抗联合化疗，无论是否联合拉泽替尼用于治疗非小细胞肺癌。

Future Oncol. 2025 Jun;21(13):1553-1568. doi: 10.1080/14796694.2025.2492456. Epub 2025 May 6.

9

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Amivantamab 联合 lazertinib 对比奥希替尼用于具有高风险疾病生物标志物的一线治疗 EGFR 突变型晚期非小细胞肺癌：MARIPOSA 的一项二次分析。

Ann Oncol. 2024 Sep;35(9):805-816. doi: 10.1016/j.annonc.2024.05.541. Epub 2024 Jun 26.

10

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.拉泽替尼与奥希替尼用于既往未治疗的表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌：来自MARIPOSA的一项随机、双盲探索性分析

J Thorac Oncol. 2025 Jul 3. doi: 10.1016/j.jtho.2025.06.030.

引用本文的文献

1

Recent advances in therapeutic strategies for non-small cell lung cancer.非小细胞肺癌治疗策略的最新进展

J Hematol Oncol. 2025 Mar 27;18(1):35. doi: 10.1186/s13045-025-01679-1.